Source: The Motley Fool
Labcorp reported 7% revenue growth to $3.8 billion in Q3 2026 with raised full-year guidance. The company faces a $125 million Medicare reimbursement headwind from proposed PAMA fee schedule changes in 2027, but plans to offset this through volume growth and cost efficiencies. Specialty testing is growing 3x faster than the broader diagnostics market, and tuck-in acquisitions from BioReference, Myriad Genetics' prenatal business, and Millennium Health are expected to be accretive to earnings in year one.
Source: Zacks Investment Research
Labcorp Holdings (LH) has surged 48.2% year-to-date, driven by expansion in specialty testing markets, AI and automation initiatives, and six consecutive quarters of margin expansion. However, currency headwinds, intense competition, and acquisition-related execution risks could limit future growth. The company maintains a Zacks Rank #3 (Hold) with a 5% earnings yield.
Source: Zacks Investment Research
Labcorp Holdings (LH), a leading healthcare diagnostics company, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a VGM Score of B. The company has attractive valuation metrics with a forward P/E ratio of 20.01 and has seen six analyst upward earnings revisions in the last 60 days, with the Zacks Consensus Estimate increasing to $18.40 per share.
Source: Zacks Investment Research
U.S. stock markets rose on Wednesday as the Federal Reserve kept interest rates unchanged at 3.75-4% and strong third-quarter earnings boosted investor confidence. The Dow Jones, Nasdaq Composite, and S&P 500 all ended in positive territory. Notable earnings beats from Seagate Technology, Amphenol Corp., and Labcorp Holdings drove their stock prices higher by 4.5%, 3.5%, and 8.8% respectively.
Source: Zacks Investment Research
Labcorp Holdings (LH) reported Q3 2026 adjusted EPS of $4.78, up 14.5% year-over-year, and revenues of $3.81 billion, up 6.9%, both beating consensus estimates. The company raised its full-year 2026 revenue guidance to 5.9-6.7% and adjusted EPS guidance to $18.30-$18.70, driven by strong organic growth across both Diagnostics and Biopharma Laboratory Services segments and margin expansion.
Source: Zacks Investment Research
Waters Corporation announced a partnership with Labcorp Holdings to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp's network of 850,000+ providers and 2,200 patient service centers beginning in late 2026. The collaboration aims to broaden cervical cancer screening options through flexible delivery methods including clinician-collected, self-collected, and at-home testing. The global HPV testing market is projected to reach $2.2 billion by 2026 with a 14.4% CAGR through 2033.
Source: Zacks Investment Research
In a comparison of two Medical Services stocks, Labcorp Holdings (LH) and Danaher (DHR), both holding a Zacks Rank #2 (Buy), Labcorp emerges as the superior value option. LH has a forward P/E of 17.67 and PEG ratio of 1.85, compared to DHR's 27.42 and 2.94 respectively. LH received a Value grade of B versus DHR's C grade, making it more attractive to value investors.
Source: Zacks Investment Research
Natera announced a strategic collaboration with TransCode Therapeutics to use its Signatera MRD test for identifying eligible patients in a Phase 2a trial evaluating TTX-MC138, an investigational therapy targeting miR-10b in colorectal cancer patients. The partnership aims to accelerate patient enrollment by detecting residual cancer in patients with no detectable disease on imaging, addressing an unmet medical need in early cancer recurrence intervention.
Source: Zacks Investment Research
OPKO Health announced an agreement to sell select BioReference assets to Labcorp for $722 million in cash plus up to $150 million in earnouts. The deal includes the 4Kscore Test, specialty testing operations, and over 80 patient service centers. OPKO aims to focus on its biopharmaceutical business, while Labcorp expects $250 million in first-year revenue from the acquisition. OPK stock rose 17.5% following the announcement.
Source: Zacks Investment Research
PACS Group shares jumped 6.2% to $47.75 on investor optimism ahead of Q3 2026 earnings release. The company is expected to report 75% earnings growth and 8.1% revenue growth. However, with unchanged consensus EPS estimates over the past 30 days, analysts caution that the stock may lack momentum for sustained gains without positive estimate revisions.
Source: GlobeNewswire Inc.
The global Decentralized Clinical Trials (DCT) market is valued at $8.8 billion in 2025 and is projected to reach $18.8 billion by 2030, growing at a 13.7% CAGR. Growth is driven by AI integration, wearable technologies, cloud-based platforms, and increased adoption of remote research capabilities across pharmaceutical, biotechnology, and contract research sectors.
Source: Zacks Investment Research
Labcorp Holdings (LH), a leading healthcare diagnostics company, receives a #3 (Hold) rating on the Zacks Rank with a VGM Score of B. The company shows attractive valuation metrics with a forward P/E ratio of 16.84 and has seen three analyst upward earnings revisions in the last 60 days, with the consensus estimate increasing to $18.32 per share for fiscal 2026.
Source: Zacks Investment Research
Danaher Corporation's Biotechnology segment drove growth with 4% reported sales increase to $1.92 billion in Q2 2026, bolstered by strong China demand and consumables sales. Despite regional headwinds in Western Europe and North America, DHR expects mid-single-digit core growth in 2026. The stock trades at a premium valuation of 24.92X forward P/E versus the industry average of 16.59X and carries a Zacks Rank #3 (Hold).
Source: Zacks Investment Research
Labcorp Holdings is expanding its specialty testing business in oncology, women's health, autoimmune disease, and neurology through strategic acquisitions and partnerships. The company is leveraging AI and automation to improve margins, with operating margins expanding 70 basis points year-over-year. However, macroeconomic uncertainty, cost inflation, and changing reimbursement policies pose risks to testing volumes and profitability.
Source: GlobeNewswire Inc.
GENFIT reported strong first-half 2026 financial results with €113.8 million in cash, driven by tripling royalty revenues from Ipsen's Iqirvo® (€21.1 million) and a €17 million milestone payment. The company is advancing three Phase 2 clinical trials including nangibotide and nitazoxanide for ACLF, while its NIS™ diagnostic technology achieved Medicare coverage for NASHnext®. Ipsen doubled Iqirvo's peak sales target to €1 billion for PBC, and IQVIA estimates NIS™-based products could exceed $1.5 billion in U.S. peak sales by 2033.